Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

被引：0
|
作者：
Yoshiya Horimoto
Yumiko Ishizuka
Yuko Ueki
Toru Higuchi
Atsushi Arakawa
Mitsue Saito
机构：
[1] Juntendo University School of Medicine,Department of Breast Oncology
[2] Juntendo University School of Medicine,Department of Human Pathology
[3] Japanese Red Cross Saitama Hospital,Department of Breast Oncology
来源：
BMC Cancer | / 22卷
关键词：
Breast cancer; HER2; Immunohistochemistry; hybridization; Trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    [J]. BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [42] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [43] HER2 Staining Intensity Shows Prognostic Impact on Patients with HER2-Positive Invasive Breast Cancer
    Chen, Yen-Ying
    Hsu, Chih-Yi
    [J]. LABORATORY INVESTIGATION, 2018, 98 : 53 - 54
  • [44] HER2 Staining Intensity Shows Prognostic Impact on Patients with HER2-Positive Invasive Breast Cancer
    Chen, Yen-Ying
    Hsu, Chih-yi
    [J]. MODERN PATHOLOGY, 2018, 31 : 53 - 54
  • [45] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    [J]. Breast Cancer, 2015, 22 : 292 - 299
  • [46] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [47] Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
    Guarneri, V.
    Dieci, M. V.
    Barbieri, E.
    Piacentini, F.
    Omarini, C.
    Ficarra, G.
    Bettelli, S.
    Conte, P. F.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (12) : 2990 - 2994
  • [48] Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
    Lee, Hee Jin
    Kim, Joo Young
    Park, So Yeon
    Park, In Ah
    Song, In Hye
    Yu, Jong Han
    Ahn, Jin-Hee
    Gong, Gyungyub
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (04) : 570 - 578
  • [49] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [50] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
12345